A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Metadoxine Extended Release 1400mg Compared With Placebo Once Daily in 300 Adults With ADHD

New Research Poster Presentation 2.54
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Metadoxine Extended Release 1400mg Compared With Placebo Once Daily in 300 Adults With ADHD

Thursday, October 23, 2014 10:00 AM

Richard Weisler, MD, University of North Carolina at Chapel Hill, Raleigh, NC

Lenard Adler, MD, New York University School of Medicine, New York, NY

Jonathan Rubin, MD, MBA, Alcobra Inc, Plymouth Meeting, PA

Yaron Daniely, MBA, PhD, Alcobra Ltd., Tel Aviv, Israel

Iris Manor, MD, ADHD unit, Geha Mental Health Center, Petach Tikva, Israel